Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | CASP1 | P29466 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | CHKA | P35790 | 1/20 | 0.66 |
| ▸ | NCF1 | P14598 | 4/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30018646 | 0.86 | NCF1 (0.79) | PKMALOX15CASP1HSD17B10CHKA | |
| SCHEMBL22659058 | 0.86 | NCF1 (0.55) | PKMALOX15CASP1HSD17B10CHKA | |
| SCHEMBL731691 | 0.86 | NCF1 (0.74) | PKMALOX15CASP1HSD17B10CHKA | |
| SCHEMBL29472100 | 0.84 | NCF1 (0.76) | PKMALOX15CASP1HSD17B10CHKA | |
| SCHEMBL22715673 | 0.84 | NCF1 (0.76) | PKMALOX15CASP1HSD17B10CHKA | |
| SCHEMBL17327869 | 0.81 | PKM (1.00) | PKMALOX15CASP1HSD17B10CHKA | |
| SCHEMBL5036271 | 0.81 | PKM (0.68) | PKMALOX15CASP1HSD17B10CHKA | |
| SCHEMBL5025316 | 0.81 | PKM (0.68) | PKMALOX15CASP1HSD17B10CHKA | |
| SCHEMBL29455010 | 0.81 | PKM (0.68) | PKMALOX15CASP1HSD17B10CHKA | |
| SCHEMBL5307848 | 0.79 | CHKA (1.00) | PKMALOX15CASP1HSD17B10CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265125-B2 | Neuropeptide Y antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050176698-A1 | Neuropeptide Y antagonists | BREU VOLKER (DE) | 2005-08-11 | — | — | US | disclosed |
| US-6900226-B2 | Neuropeptide Y antagonists | HOFFMAN-LA ROCHE INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1318981-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-18 | — | — | EP | disclosed |
| US-20020052356-A1 | Neuropeptide Y antagonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-02 | — | — | US | disclosed |
| WO-2002020488-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176698-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | PKM 3581/4885ALOX15 3348/4885CASP1 1194/4885 |
| US-20020052356-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | PKM 3581/4885ALOX15 3348/4885CASP1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.